Literature DB >> 33389070

Longitudinal growth patterns and final height in childhood-onset systemic lupus erythematosus.

Pondtip Jongvilaikasem1, Pornpimol Rianthavorn2.   

Abstract

Patients with childhood-onset systemic lupus erythematosus (cSLE) are at risk of becoming short adults. To evaluate the growth patterns and risk factors of short final height, a retrospective study was conducted in 97 patients (87 females, 90%) with cSLE who grew from the time of diagnosis and reached their final height. The primary outcome was the final height. Participants were divided into participants with short final height (final height standard deviation score (HSDS) < - 2, n = 22, 23%) and participants with normal final height (final HSDS ≥ - 2, n = 75, 77%). At diagnosis, the mean age was 11.3 ± 2.4 years and HSDS was - 0.5 ± 1.3. The participants reached the final height of 1.51 ± 0.08 m (final HSDS - 1.3 ± 0.1) at mean age of 16.2 ± 2.3 years. The HSDS of participants with short final height steadily declined throughout the course of SLE (p = 0.02), and were significantly lower than participants with normal final height at any time point (p < 0.001). In participants with normal final height, HSDS significantly declined from baseline until 2 years after diagnosis (p = 0.01), and then became stable thereafter. The independent risk factors for short final height were the male sex, short stature at diagnosis, low body weight at final height, and cumulative corticosteroid dose.
Conclusion: A substantial number of the participants with cSLE became short adults. Adequate nutrition and corticosteroid minimization should be emphasized in patients at high risk for short final height. What is known? • Growth failure is common in SLE due to many risk factors including chronic inflammation, malnutrition, and long-term use of corticosteroids. • In comparison to growth failure, final height is a better indicator of growth as the prevalence of growth failure is variable depending on definitions, patient age and pubertal status. What is new? • Nearly one fourth of children with SLE have short final height. • The independent risk factors for short final height were the male sex, short stature at diagnosis, low body weight at final height, and cumulative corticosteroid dose.

Entities:  

Keywords:  Child; Growth disorders; Lupus erythematosus; Lupus nephritis

Year:  2021        PMID: 33389070     DOI: 10.1007/s00431-020-03910-2

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  32 in total

1.  Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus.

Authors:  M Bandeira; S Buratti; M Bartoli; C Gasparini; L Breda; A Pistorio; S Grassi; M G Alpigiani; G Barbano; L L Janz-Junior; A Martini; A Ravelli
Journal:  Lupus       Date:  2006       Impact factor: 2.911

2.  A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus.

Authors:  Raul Gutiérrez-Suárez; Nicolino Ruperto; Roberto Gastaldi; Angela Pistorio; Enrico Felici; Rubén Burgos-Vargas; Alberto Martini; Angelo Ravelli
Journal:  Arthritis Rheum       Date:  2006-09

3.  Growth Pattern in Children with Systemic Lupus Erythematosus.

Authors:  Eiman Abdalla; Lakshamanan Jeyaseelan; Irfan Ullah; Reem Abdwani
Journal:  Oman Med J       Date:  2017-07

Review 4.  Advances in the care of children with lupus nephritis.

Authors:  Scott E Wenderfer; Natasha M Ruth; Hermine I Brunner
Journal:  Pediatr Res       Date:  2016-11-17       Impact factor: 3.756

Review 5.  Growth and the Growth Hormone-Insulin Like Growth Factor 1 Axis in Children With Chronic Inflammation: Current Evidence, Gaps in Knowledge, and Future Directions.

Authors:  S C Wong; R Dobie; M A Altowati; G A Werther; C Farquharson; S F Ahmed
Journal:  Endocr Rev       Date:  2015-12-31       Impact factor: 19.871

6.  Long-term renal outcomes of childhood-onset global and segmental diffuse proliferative lupus nephritis.

Authors:  Pornpimol Rianthavorn; Athitaya Buddhasri
Journal:  Pediatr Nephrol       Date:  2015-06-09       Impact factor: 3.714

7.  A longitudinal PRINTO study on growth and puberty in juvenile systemic lupus erythematosus.

Authors:  Marite Rygg; Angela Pistorio; Angelo Ravelli; Mohamad Maghnie; Natascia Di Iorgi; Brigitte Bader-Meunier; Carlos Da Silva; Rosa Roldan-Molina; Judith Barash; Cristina Dracou; Sylvie Gandon Laloum; Katerina Jarosova; Chantal Job Deslandre; Isabelle Koné-Paut; Franco Garofalo; Joseph Press; Claudia Sengler; Tsivia Tauber; Alberto Martini; Nicolino Ruperto
Journal:  Ann Rheum Dis       Date:  2011-10-13       Impact factor: 19.103

8.  Clinical features and long-term outcomes of systemic lupus erythematosus: comparative data of childhood, adult and late-onset disease in a national register.

Authors:  S Sousa; M J Gonçalves; L S Inês; G Eugénio; D Jesus; S Fernandes; G Terroso; V C Romão; M Cerqueira; A Raposo; M Couto; P Nero; G Sequeira; T Nóvoa; J A Melo Gomes; J Canas da Silva; L Costa; C Macieira; C Silva; J A P Silva; H Canhão; M J Santos
Journal:  Rheumatol Int       Date:  2016-03-15       Impact factor: 2.631

9.  The outcome of patients with renal involvement in pediatric-onset systemic lupus erythematosus--a 20-year experience in Asia.

Authors:  P-Y Lee; K-W Yeh; T-C Yao; W-I Lee; Y-J Lin; J-L Huang
Journal:  Lupus       Date:  2013-08-21       Impact factor: 2.911

10.  Chronic Kidney Disease: Treatment of Comorbidities I: (Nutrition, Growth, Neurocognitive Function, and Mineral Bone Disease).

Authors:  Amy J Kogon; Lyndsay A Harshman
Journal:  Curr Treat Options Pediatr       Date:  2019-04-15
View more
  1 in total

1.  An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus.

Authors:  Vitor Cavalcanti Trindade; Magda Carneiro-Sampaio; Eloisa Bonfa; Clovis Artur Silva
Journal:  Paediatr Drugs       Date:  2021-07-10       Impact factor: 3.022

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.